ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Impax Pharmaceuticals 

30831 Huntwood Avenue

Hayward  California  94544  U.S.A.
Phone: 510-476-2000 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






 Company News
Impax Pharmaceuticals (IPXL) Announces Presentation of RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data at the American Academy of Neurology 2013 Annual Meeting 3/19/2013 9:42:47 AM
Impax Pharmaceuticals (IPXL) Fails to Win Approval for Parkinson's Drug 1/22/2013 7:47:01 AM
Impax Pharmaceuticals (IPXL): FDA Extends Review on Rytary NDA 10/12/2012 7:33:10 AM
Impax Pharmaceuticals Release: Data from ASCEND-PD Phase III Study of IPX066 to be Presented at the American Academy of Neurology Conference 4/18/2012 9:57:16 AM
FDA Accepts Impax Pharmaceuticals NDA Filing for IPX066 for the Treatment of Idiopathic Parkinson’s Disease 2/23/2012 6:16:33 AM
Impax Pharmaceuticals Gains Rights for US Sales of AstraZeneca PLC (AZN)'s Zomig; Paying $130 Million in 2012 2/1/2012 7:19:51 AM
Impax Pharmaceuticals Submits New Drug Application for IPX066 in Parkinson’s Disease 12/21/2011 1:47:53 PM
Impax Pharmaceuticals Initiates Phase IIb Trial of IPX159 in Restless Legs Syndrome 12/19/2011 9:39:35 AM
Impax Pharmaceuticals Completes Enrollment in ASCEND-PD Phase III Trial of IPX066 in Parkinson’s Disease 7/26/2011 7:07:15 AM
Impax Pharmaceuticals Awarded Michael J. Fox Foundation Grant for Ongoing Research of IPX066 for Parkinson’s Disease 7/14/2011 9:06:40 AM
12